Tag: Ranibizumab

Susvimo was first FDA-approved in October 2021 for wet age-related macular degeneration, but a voluntary recall in 2022 due to manufacturing issues created a temporary hurdle. Today, following a successful relaunch in 2024, Susvimo is not only FDA-approved but also carries multiple indications for treating serious retinal conditions.

Despite common confusion, a recent FDA approval highlights that Cimerli and Avastin are fundamentally distinct medications. To be clear, **is Cimerli the same as Avastin?** The answer is no, as Cimerli is a biosimilar drug used for retinal diseases while Avastin is an original biologic primarily for cancer treatment.

Anti-VEGF treatments have become the standard of care for many serious retinal conditions, yet studies indicate that Eylea (aflibercept) may offer a longer duration of action compared to Accentrix (ranibizumab), often resulting in less frequent administration. Understanding **what is the difference between Eylea and Accentrix?** is crucial for patients and healthcare providers determining the best therapeutic approach for conditions like wet macular degeneration and diabetic macular edema.

The list price for Lucentis (ranibizumab), often misspelled as Accentrix, can be approximately $1,575 to $2,000 per injection [1.2.2, 1.2.4]. What is the cost of Accentrix injection and what factors determine the final price for patients needing this critical eye treatment?

Originally approved by the FDA in 2006 for wet age-related macular degeneration, **Accentrix injection** is a crucial treatment for several serious eye diseases. This medication, known by its active ingredient ranibizumab, works by targeting the abnormal blood vessel growth that causes vision loss.